TScan Therapeutics, Inc. — Director's Dealing 2021

Sep 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TScan Therapeutics, Inc. (TCRX)
CIK: 0001783328
Period of Report: 2021-09-07

Reporting Person: ZDRAVESKI ZORAN (Chief Legal Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-07	Stock Option (right to buy)	$8.99	A	150000	Acquired	2031-09-06	Voting Common Stock (150000)	Direct

Footnotes

F1: The shares subject to this option will vest with respect to 25% of the shares after 12 months of continuous service to the Issuer following September 7, 2021, and the balance will vest in equal monthly installments over the next 36 months of continuous service to the Issuer.